Abstracts tagged "autoantibodies"

Abstract Number: 2170 • 2017 ACR/ARHP Annual Meeting
Near Patient Detection of Anti-MDA5 Antibodies Using Photonic Ring Immunoassays
Makoto Miyara¹, Rémi Chieze², Yurdagul Uzunhan³, Jean- Luc Charuel⁴, Pascale Ghillani-Dalbin⁴, Sasi Mudumba⁵, Alice Wu⁵, Hilario Nunes³, Zahir Amoura⁶, Rufus Burlingame⁵ and Lucile Musset¹, ¹Department of immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ²department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁴Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁵Genalyte Inc., San Diego, CA, ⁶Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: The presence of anti-MDA5 antibody is associated with amyopathic dermatomyositis and/or rapidly progressive interstitial lung disease that can be fatal.In the latter case, it…
Abstract Number: 724 • 2017 ACR/ARHP Annual Meeting
Antibodies Against the Chemokine Receptors CXCR3 and CXCR4 Predict Progressive Lung Fibrosis in Systemic Sclerosis (SSc)
Gabriela Riemekasten¹, Elise Siegert² and Harald Heidecke³, ¹Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany, ²Rheumatology and Clinical Immunology, University Hospital Charité, Berlin, Germany, ³CellTrend GmbH Luckenwalde, Luckenwalde, Germany
Background/Purpose: Chemokine receptors CXCR3 and CXCR4 are involved in immune cell migration and in the pathogenesis of inflammatory fibrosis, a key feature of systemic sclerosis…
Abstract Number: 1672 • 2017 ACR/ARHP Annual Meeting
Cytokines and Autoantibody Cluster-Interaction in Systemic Lupus Erythematosus. a Systems Medicine Approach
Julian Barahona-Correa, Yovana Pacheco, Diana M. Monsalve, Manuel Rojas, Yhojan Rodríguez, Juliana Saavedra, Mónica Rodríguez-Jiménez, Ruben Mantilla, Carolina Ramírez-Santana, Nicolás Molano-González and Juan-Manuel Anaya, Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
Background/Purpose: Evidence supports the existence of different sub-phenotypes and the pivotal role of cytokines and autoantibodies in systemic lupus erythematosus (SLE). Cytokines interact in a…
Abstract Number: 2335 • 2017 ACR/ARHP Annual Meeting
Antiendothelial Cell Antibodies in Juvenile Dermatomyositis: A Proteomics-Based Approach
Rie Karasawa¹, Mayumi Tamaki¹, Toshiko Sato¹, Megumi Tanaka¹, Kazuo Yudoh¹ and James Jarvis², ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Department of Genetics, Genomics & Bioinformatics, University at Buffalo, Buffalo, NY
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic disorder of childhood characterized by muscle inflammation and vasculopathy. The mechanisms of the blood vessel injury in JDM…
Abstract Number: 26 • 2017 ACR/ARHP Annual Meeting
Single B Cell Analysis Revealed the Relationship Among the Cytokine Profile, Antibody Affinity, and Pathogenic Roles of Autoantigen-Reactive B Cells in Systemic Sclerosis
Takemichi Fukasawa¹, Ayumi Yoshizaki², Satoshi Ebata¹, Kouki Nakamura¹, Ryosuke Saigusa¹, Takashi Yamashita¹, Yoshihide Asano³, Yutaka Kazoe⁴, Kazuma Mawatari⁴, Takehiko Kitamori⁴ and Shinichi Sato⁵, ¹Dermatology, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Applied Chemistry, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ⁴Applied Chemistry, University of Tokyo, Graduate School of Engineering, Tokyo, Japan, ⁵Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan
Background/Purpose: Recent studies have indicated that B cells play critical roles in systemic autoimmunity and disease expression through various functions such as induction of the…
Abstract Number: 727 • 2017 ACR/ARHP Annual Meeting
Survival and Clinical-Capillaroscopic Characteristics of French Canadian Systemic Sclerosis Patients: Analysis Based on Systemic Sclerosis Autoantibodies and the Novel Anti-BICD2 Autoantibody
Boyang Zheng¹, Michael Mahler², Jean-Luc Senécal³, France Joyal⁴ and Martial Koenig⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada, ²Research and Development, Inova Diagnostics, San Diego, CA, ³Rheumatology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada, ⁴Internal Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada, ⁵Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) autoantibodies (aAbs) are invaluable for SSc diagnosis and prognosis. Anti-centromere (ACA), anti-topoisomerase I (ATA) and anti-RNA polymerase III (RNAP) have been…
Abstract Number: 1693 • 2017 ACR/ARHP Annual Meeting
To What Extend Do Auto-Antibodies Help to Identify High-Risk Patients in Systemic Sclerosis?
Maaike Boonstra¹, Jaap Bakker², Maarten K. Ninaber³, Nina Ajmone Marsan⁴, Tom W.J. Huizinga⁵ and Jeska K. de Vries-Bouwstra⁶, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, Netherlands, ³Pulmonology, Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands, ⁴Heart and Lung Center, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Leiden, Netherlands
Background/Purpose: In Systemic Sclerosis tight monitoring during the first years of disease is required in order to detect organ complications timely. Although a clear pathophysiologic…
Abstract Number: 2602 • 2017 ACR/ARHP Annual Meeting
Identification of Clinical and Serological Predictive Factors of Response to Rituximab Treatment in Systemic LUPUS Erythematosus (SLE) Patients
Hiurma Sanchez-Perez¹ and David A. Isenberg², ¹Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Response to Rituximab (RTX) varies significantly between Systemic Lupus Erythematosus (SLE) patients. Ethnicity may play a role in these differences, and a possible relationship…
Abstract Number: 27 • 2017 ACR/ARHP Annual Meeting
Effects of High Titers of Anti-Chimeric Antibodies Following Rituximab
Roberta Fenoglio¹, Laura Solfietti¹, Savino Sciascia² and Dario Roccatello¹, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Monoclonal antibodies (MoAbs) are highly successful in treating various immunological disorders. The development of anti-drug antibodies (ADA) against the therapeutic MoAb is relatively common.…
Abstract Number: 849 • 2017 ACR/ARHP Annual Meeting
Tumor TIF1 Mutations and Loss of Heterozygosity Related to Cancer Associated Myositis
Iago Pinal-Fernandez¹, Berta Ferrer-Fabregas², Ernesto Trallero-Araguas¹, Eva Balada¹, Maria Angeles Martinez³, Jose Cesar Milisenda⁴, Gloria Aparicio-Español⁵, Moises Labrador-Horrillo¹, Vicente Garcia-Patos¹, Josep Maria Grau-Junyent⁴ and Albert Selva O'Callaghan⁶, ¹Internal Medicine, Autoimmune Diseases Unit. Vall d´Hebron Hospital, Barcelona, Spain, ²Pathology, Vall d´Hebron, Barcelona, Spain, ³Immunology, Immunology Department, Barcelona, Spain, ⁴Muscle Research Group and Ciberer, Hospital Clinic Provincial, Barcelona, Spain, ⁵Dermatology, Vall d´Hebron Hospital, Barcelona, Spain, ⁶Internal Medicine, Hospital Universitari General Vall d'Hebron, Barcelona, Spain
Background/Purpose: To analyze the influence of genetic alterations and differential expression of the TIF1 genes in the pathophysiology of cancer-associated myositis (CAM). Methods: Whole exome…
Abstract Number: 1700 • 2017 ACR/ARHP Annual Meeting
Focusing on Pulmonary Vascular Disease at Early Stage of Systemic Sclerosis: Exercise-Induced Pulmonary Arterial Hypertension and Gene Co-Expression Networks Involved in Its Pathogenesis
Yoshinobu Koyama¹, Soichiro Fuke², Yoshiharu Sato³ and Toshie Higuchi¹, ¹Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, ²Department of Cardiology, Japan Red Cross Okayama Hospital, Okayama, Japan, ³DNA Chip Research Inc, Yokohama, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) is prominent as a vascular involvement in systemic sclerosis (SSc), which remains a leading cause of death in spite of…
Abstract Number: 2649 • 2017 ACR/ARHP Annual Meeting
Anti-Suprabasin Antibody; A Novel Autoantibody May Contribute to the Pathogenesis of Neuropsychiatric Systemic Lupus Erythematosus
Kunihiro Ichinose¹, Kaname Ohyama², Kaori Furukawa¹, Osamu Higuchi³, Shunya Nakane⁴, Masataka Umeda¹, Tomohiro Koga¹, Takashi Igawa¹ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Course of Pharmaceutical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Clinical Research, Nagasaki Kawatana Medical Center, Nagasaki, Japan, ⁴Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Background/Purpose: Systemic lupus erythematosus (SLE), an autoimmune disorder characterized by the production of pathogenic autoantibodies and inflammatory mediators, involves multiple organ systems. Neuropsychiatric systemic lupus…
Abstract Number: 84 • 2017 Pediatric Rheumatology Symposium
Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Takayuki Kishi¹, William Warren-Hicks², Michael Ward³, Nastaran Bayat¹, Lan Wu¹, Gulnara Mamyrova⁴, Ira N. Targoff⁵, Frederick Miller¹, Lisa G. Rider¹ and the Childhood Myositis Heterogeneity Study Group, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, ²EcoStat, Inc., Mebane, NC, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Factors affecting treatment (Rx) responses in juvenile dermatomyositis (JDM) are not well understood. We examined a large JDM registry for predictors of excellent Rx…
Abstract Number: 16 • 2017 Pediatric Rheumatology Symposium
Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups
Hanna Kim¹, Angélique Biancotto², Foo Cheung³, Terrance P. O'Hanlon⁴, Ira N. Targoff⁵, Yan Huang⁶, Frederick Miller⁴, Raphaela Goldbach-Mansky⁶ and Lisa G. Rider⁴, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ³Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease. Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes…
Abstract Number: 85 • 2017 Pediatric Rheumatology Symposium
Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America
Gulnara Mamyrova¹, Takayuki Kishi², Ira N Targoff³, Rodolfo V Curiel¹, Frederick W Miller², Lisa G Rider^1,2 and The Childhood Myositis Heterogeneity Collaborative Study Group, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, ³VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Anti-MDA5 Abs have been reported to associate with clinically amyopathic and classic dermatomyositis (DM), with severe progressive interstitial lung disease (ILD) and poor prognosis…

« Previous Page
1
…
8
9
10
11
12
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].